[1]
|
GORDON C, AMISSAH-ARTHUR M B, GAYED M, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults[J]. Rheumatology (Oxford), 2018, 57(1): e1. doi: 10.1093/rheumatology/kex286 |
[2]
|
王涛, 江超, 赵萍, 等. 系统性红斑狼疮病人外周血血清TGF-β1的表达及临床意义[J]. 蚌埠医学院学报, 2019, 44(7): 868. |
[3]
|
KAEWRAEMRUAEN C, RITPRAJAK P, HIRANKARN N. Dendritic cells as key players in systemic lupus erythematosus[J]. Asian Pac J Allergy Immunol, 2020, 38(4): 225. |
[4]
|
YAMAUCHI M, MORIYAMA M, HAYASHIDA J N, et al. Myeloid dendritic cells stimulated by thymic stromal lymphopoietin promote Th2 immune responses and the pathogenesis of oral lichen planus[J]. PLoS One, 2017, 12(3): e0173017. doi: 10.1371/journal.pone.0173017 |
[5]
|
GUIDUCCI C, GONG M, XU Z, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus[J]. Nature, 2010, 465(7300): 937. doi: 10.1038/nature09102 |
[6]
|
CELHAR T, FAIRHURST AM. Toll-like receptors in systemic lupus erythematosus: potential for personalized treatment[J]. Front Pharmacol, 2014, 5: 265. |
[7]
|
CLANCY RM, MARKHAM AJ, BUYON JP. Endosomal Toll-like receptors inclinically overt and silent autoimmunity[J]. Immunol Rev, 2016, 269(1): 76. doi: 10.1111/imr.12383 |
[8]
|
GLADMAN DD, IBANEZ D, UROWITZ MB. Systemic lupus erythematosus disease activity index 2000[J]. J Rheumatol, 2002, 29(2): 288. |
[9]
|
TEKTONIDOU MG, LEWANDOWSKI LB, HU J, et al. Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016[J]. Ann Rheum Dis, 2017, 76(12): 2009. doi: 10.1136/annrheumdis-2017-211663 |
[10]
|
JORGE AM, LU N, ZHANG Y, et al. Unchanging premature mortality trends in systemic lupus erythematosus: a general population-based study (1999-2014)[J]. Rheumatology (Oxford), 2018, 57(2): 337. doi: 10.1093/rheumatology/kex412 |
[11]
|
DORNER T, FURIE R. Novel paradigms in systemic lupus erythematosus[J]. Lancet, 2019, 393(10188): 2344. doi: 10.1016/S0140-6736(19)30546-X |
[12]
|
DURCAN L, O'DWYER T, PETRI M. Management strategies and future directions for systemic lupus erythematosus in adults[J]. Lancet, 2019, 393(10188): 2332. doi: 10.1016/S0140-6736(19)30237-5 |
[13]
|
TSAO JT, HSIEH SC, CHIANG BL, et al. Altered IL-10 and TNF-α production in peripheral blood mononuclear cells of systemic lupus erythematosus patients after Toll-like receptor 2, 4, or 9 activation[J]. Clin Exp Med, 2012, 12(3): 153. doi: 10.1007/s10238-011-0161-6 |
[14]
|
CHEN JQ, SZODORAY P, ZEHER M. Toll-like receptor pathways in autoimmune diseases[J]. Clin Rev Allergy Immunol, 2016, 50(1): 1. doi: 10.1007/s12016-015-8473-z |
[15]
|
PATRA MC, ACHEK A, KIM GY, et al. A novel small-molecule inhibitor of endosomal TLRs reduces inflammation and alleviates autoimmune disease symptoms in murine models[J]. Cells, 2020, 9(7): 1648. doi: 10.3390/cells9071648 |
[16]
|
DOMINGUES R, DE CARVALHO GC, AOKI V, et al. Activation of myeloid dendritic cells, effector cells and regulatory T cells in lichen planus[J]. J Transl Med, 2016, 14(1): 171. doi: 10.1186/s12967-016-0938-1 |
[17]
|
DOMINGUES R, DE CARVALHO GC, DA SILVA OLIVEIRA LM, et al. The dysfunctional innate immune response triggered by Toll-like receptor activation is restored by TLR7/TLR8 and TLR9 ligands in cutaneous lichen planus[J]. Br J Dermatol, 2015, 172(1): 48. doi: 10.1111/bjd.13214 |
[18]
|
JIN MS, KIM SE, HEO JY, et al. Crystal structure of the TLR1-TLR2 heterodimer induced by binding of a triacylated lipopeptide[J]. Cell, 2007, 130(6): 1071. doi: 10.1016/j.cell.2007.09.008 |
[19]
|
PARK BS, SONG DH, KIM HM, et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex[J]. Nature, 2009, 458(7242): 1191. doi: 10.1038/nature07830 |
[20]
|
UENO H, KLECHEVSKY E, MORITA R, et al. Dendritic cell subsets in health and disease[J]. Immunol Rev, 2007, 219: 118. doi: 10.1111/j.1600-065X.2007.00551.x |
[21]
|
KIRCHNER M, SONNENSCHEIN A, SCHOOFS S, et al. Surface expression and genotypes of Toll-like receptors 2 and 4 in patients with juvenile idiopathic arthritis and systemic lupus erythematosus[J]. Pediatr Rheumatol Online J, 2013, 11(1): 9. doi: 10.1186/1546-0096-11-9 |
[22]
|
吕迎霞, 杨俊梅, 郑莉娟, 等. SLE患儿外周血TLR-4、HMGB1的表达及临床意义[J]. 检验医学, 2020, 35(11): 1143. |
[23]
|
刘昱. Toll样受体2(TLR2)在系统性红斑狼疮发病机制中的作用及其分子机制[D]. 长沙: 中南大学, 2014. |
[24]
|
张文兰, 胡同平, 王慧, 等. 系统性红斑狼疮患者单核细胞中TLR-4、IRAK-M的表达及意义[J]. 免疫学杂志, 2013, 29(6): 510. |
[25]
|
黄莉, 盛伟松. 高迁移率族蛋白B1及Toll样受体4在儿童系统性红斑狼疮中的临床意义[J]. 中华风湿病学杂志, 2019, (6): 365. |
[26]
|
WANG X, WONG K, OUYANG W, et al. Targeting IL-10 family cytokines for the treatment of human diseases[J]. Cold Spring Harb Perspect Biol, 2019, 11(2): a028548. doi: 10.1101/cshperspect.a028548 |
[27]
|
吕甜甜. 白细胞介素-10与系统性红斑狼疮相关性的分子流行病学研究[D]. 合肥: 安徽医科大学, 2018. |
[28]
|
沈茹, 李艳君, 林丽佳. 系统性红斑狼疮患儿外周血IL-6、IL-10、IL-17水平变化及其在单个核细胞中的表达研究[J]. 分子诊断与治疗杂志, 2017, 9(6): 371. |
[29]
|
杨依骏, 杜建钢, 朱琴芳, 等. 系统性红斑狼疮患者血清IL-10和IL-17水平检测的临床意义[J]. 现代检验医学杂志, 2017, 32(3): 71. |